These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28143957)

  • 1. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
    Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling.
    Chudasama KK; Winnay J; Johansson S; Claudi T; König R; Haldorsen I; Johansson B; Woo JR; Aarskog D; Sagen JV; Kahn CR; Molven A; Njølstad PR
    Am J Hum Genet; 2013 Jul; 93(1):150-7. PubMed ID: 23810379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Burke JE
    Front Immunol; 2018; 9():575. PubMed ID: 29616047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell acute lymphoblastic leukemia.
    Marzollo A; Maestrini G; La Starza R; Elia L; Malfona F; Pierini T; Tretti Parenzan C; Coppe A; Bortoluzzi S; Biffi A; Mecucci C; Bresolin S; Testi AM
    Am J Hematol; 2020 Dec; 95(12):E335-E338. PubMed ID: 32936972
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
    Hofmann BT; Jücker M
    Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APDS2 and SHORT Syndrome in a Teenager with PIK3R1 Pathogenic Variant.
    Ramirez L; Tamayo W; Ale H
    J Clin Immunol; 2020 Oct; 40(7):1020-1025. PubMed ID: 32778990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PIK3R1 mutation of SHORT syndrome in a Chinese female with diffuse thyroid disease: a case report and review of literature.
    Sun L; Zhang Q; Li Q; Tang Y; Wang Y; Li X; Li N; Wang J; Wang X
    BMC Med Genet; 2020 Oct; 21(1):215. PubMed ID: 33129256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
    Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
    Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3R1 mutations in SHORT syndrome.
    Schroeder C; Riess A; Bonin M; Bauer P; Riess O; Döbler-Neumann M; Wieser S; Moog U; Tzschach A
    Clin Genet; 2014 Sep; 86(3):292-4. PubMed ID: 23980586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.
    Cheung LW; Walkiewicz KW; Besong TM; Guo H; Hawke DH; Arold ST; Mills GB
    Elife; 2015 Jul; 4():e06866. PubMed ID: 26222500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
    Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
    Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel PIK3R1 mutation of SHORT syndrome: A case report with a 6-month follow up.
    Yin X; Liu J; Feng R; Xu M; Liu J
    J Diabetes Investig; 2021 Oct; 12(10):1919-1922. PubMed ID: 33742773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of p85α Alterations in Cancer.
    Marshall JDS; Whitecross DE; Mellor P; Anderson DH
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30650664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy.
    Thauvin-Robinet C; Auclair M; Duplomb L; Caron-Debarle M; Avila M; St-Onge J; Le Merrer M; Le Luyer B; Héron D; Mathieu-Dramard M; Bitoun P; Petit JM; Odent S; Amiel J; Picot D; Carmignac V; Thevenon J; Callier P; Laville M; Reznik Y; Fagour C; Nunes ML; Capeau J; Lascols O; Huet F; Faivre L; Vigouroux C; Rivière JB
    Am J Hum Genet; 2013 Jul; 93(1):141-9. PubMed ID: 23810378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.
    Jaiswal BS; Janakiraman V; Kljavin NM; Chaudhuri S; Stern HM; Wang W; Kan Z; Dbouk HA; Peters BA; Waring P; Dela Vega T; Kenski DM; Bowman KK; Lorenzo M; Li H; Wu J; Modrusan Z; Stinson J; Eby M; Yue P; Kaminker JS; de Sauvage FJ; Backer JM; Seshagiri S
    Cancer Cell; 2009 Dec; 16(6):463-74. PubMed ID: 19962665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism.
    Thapa N; Chen M; Cryns VL; Anderson R
    Cell Rep; 2024 May; 43(5):114119. PubMed ID: 38630589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
    Thorpe LM; Spangle JM; Ohlson CE; Cheng H; Roberts TM; Cantley LC; Zhao JJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(27):7095-7100. PubMed ID: 28630349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.